Cardium Therapeutics (CXM)

So,hier gibt es keinen Cardium Thread mehr auf Ariva,deshalb mach ich einen auf,neue WKN ist A1W2PN ,gleich mal ganz aktuell von heute:

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- LifeAgain Insurance Solutions Inc., a wholly-owned subsidiary of Cardium Therapeutics (NYSE MKT: CXM), today announced its support of Life Insurance Awareness Month.  The campaign, taking place during September, is sponsored by the Life and Health Insurance Foundation for Education (LIFE).  LIFE is dedicated to helping individuals take personal financial responsibility through the ownership of life insurance and other related insurance, including disability and long-term care insurance, to ensure their loved ones are financially protected.  

(Logo: photos.prnewswire.com/prnh/20130919/LA82808LOGO)

While life insurance rates for the traditional insurable population are now more affordable than ever, the percentage of U.S. households owning individual life insurance has steadily declined over the past 25 years—from 62 percent in 1985 to an all-time 50-year low of 44 percent in 2010.  However, for cancer patients who really do "need life insurance," their hands often are tied. Life insurance typically only becomes an option after five years of being cancer free.  Even then, it can be an uphill battle depending on the type, stage, grade of the cancer, and the treatment plan.

To address this problem, LifeAgain recently launched its BlueMetric™ Select term life insurance program for men with active localized prostate cancer.  The BlueMetric Select program was developed based on LifeAgain's Advanced Medical Data Analytics Platform Technology (ADAPT™).  Prostate cancer is one of the most prevalent forms of cancer in the United States. Currently, men with elevated prostate-specific antigen (PSA) scores and active localized prostate cancer usually are considered uninsurable based on traditional underwriting standards.  LifeAgain's BlueMetric Select program was specifically designed to assist life insurance companies to provide eligible men with term life insurance coverage following a cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.  Additional information about the BlueMetric Select Program is available at www.lifeagain.com.

About The Life and Health Insurance Foundation for Education

The Life and Health Insurance Foundation for Education (LIFE) is a nonprofit organization dedicated to helping consumers make smart insurance decisions to safeguard their families' financial futures. LIFE's mission is to educate the public about the essential role of life and health insurance in sound financial and retirement planning and the value added by insurance agents and other financial advisors. Visit www.lifehappens.org.

About LifeAgain

LifeAgain Insurance Solutions, Inc. is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of "survivable risk" term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain's initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions.  Additional information is available at www.lifeagain.com

MFG
Chali

Endlich ist es Cardium gelungen Excellagen zu vermarkten:

Excellagen ist ein Wundheilungspräparat, dass in Gelform aufgetragen wird.
Die Studienergebnisse haben eine bis 30% schnellere Wundheilung als
bei der gegenwärtigen Standardanwendung (Regranex Gel) aufgezeigt.
Der Markt für die Anwendung an Fußgeschwüren von Diabetikern wird auf bis zu
2 Mrd Dollar geschätzt. Entsprechend groß ist das Potenzial dieser kleinen Firma.
Nach erfolgter Zulassung wird Excellagen wohl auslizensiert und könnte
schätzungsweise alleine 300 Mio an Upfront Payments einbringen. Wohlgemerkt
ist CXM mit 6 Mio Dollar bewertet. Wie stichhaltig diese Schätzungen allerdings sind
überlasse ich jedem einzelnen selbst zu beurteilen

Chalifmann

SAN DIEGO, Aug. 7, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into a distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen® advanced wound care product in Germany and Switzerland.  Kasiak Holdings is focused on developing stem cell-based therapeutics for the treatment of diabetic foot ulcers.  Kasiak Holdings is affiliated with Kasiak Research, which is an operating unit of India-based Bharat Serums and Vaccines, that develops and manufactures specialized biological, pharmaceutical and biotechnology products.  

(Logo: photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Cardium's FDA-cleared Excellagen is an aseptically-manufactured, quaternary fibrillar Type I bovine collagen homogenate that is configured into a staggered array of three-dimensional, triple helical, telopeptide-deleted, tropocollagen molecules.  This linear array forms a flowable, biocompatible and bioactive structural matrix that can promote chemotaxis, cellular adhesion, migration and proliferation to stimulate tissue formation. The Excellagen homogenate represents a new product delivery platform that allows for the potential development of a portfolio of advanced tissue regeneration therapeutic opportunities that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells and conditioned cell media.

About Excellagen
Excellagen is a syringe-based, professional-use, pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen homogenate that functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.  Excellagen's FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen's unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.

There have been important, positive findings reported by physicians using Excellagen as part of Cardium's physician sampling, patient outreach and market "seeding" programs.  In several case studies, physicians reported a rapid onset of the growth of granulation tissue in a wide array of wounds, including non-healing diabetic foot ulcers (consistent with the results of Cardium's Matrix clinical study), as well as pressure ulcers, venous ulcers and Mohs surgical wounds.  In certain cases, rapid granulation tissue growth and wound closure have been achieved with Excellagen following unsuccessful treatment with other advanced wound care approaches.  From a dermatology perspective, a previously unexplored vertical market, remarkable healing responses have been observed following Mohs surgery for patients diagnosed with squamous and basal cell carcinomas, including deep surgical wounds extending to the periosteum (a membrane that lines the outer surface of bones).  Additionally, because of the easy-use and platelet activating capacity, physicians have been employing Excellagen in severe non-healing wounds at near-amputation status, in combination with autologous platelet-rich plasma therapy and collagen sheet products.  These case studies and positive physician feedback provide additional support of Excellagen's potential utility as an important new tool to help promote the wound healing process.  Excellagen case studies are available at www.excellagen.com/surgical-wounds.html.

MFG
Chali

Hm, der Kurs bröckelt aber nun unter geringen Umsätzen stetig ab. Wann lohnt denn hier ein Einstieg?  

Sag mal,bist du in Tesla wieder drin ? Meiner Meinung nach lohnt ein einstieg in Cardium gerade jetzt,auch wenn es momentan etwas bröckelt ! Übrigens,hast du im Organovo Thread den neusten Bericht gelesen ? Man ist nun schon soweit menschliche Organe in Miniformat zu drucken,und es sei nur noch eine Frage der Zeit,bis Originalgrösse möglich ist ! Wichtig für Cardium wäre die 1 dollar Marke kurzfristig ,damit es keine Listing Probs gibt,ich denke das klappt aber !

MFG
Chali

Nein, leider nicht mehr, hatte mich mit einem moderaten Gewinn verabschiedet. Nun jedoch all-time-high bei 180 USD, grrr.......

Cardium müsste sich verhundertfachen,um genauso teuer zu sein wie INO oder ONVO !
Das Potential ist meiner Meinung nach klar vorhanden,also ich bleib dabei !

Tesla doppelt so teuer wie Porsche und fast halb so teuer wie Daimler,das kann nicht mehr lange gut gehen,also mach dir nix draus und ärgere dich nicht ! Ich hab übrigens vor Cardium weiter aufzustocken,sobald Kohle da ist,die Aktie ist im Moment total unter Radar ......

Nüchtern betrachtet sieht es schon übel aus um die company,die Aktie hat sich seit 2009 gehundertstelt und man ist fast pleite mit noch 600.000 Dollar Cash. Ich habe deshalb meine Position geschlossen und mit 6% Verlust verkauft,iss mir zu heiss :

...hättest Du noch ein bisschen gewartet, hättest Du heute mit Gewinn verkaufen können.

Plus 13 %! Wie d´es machst, isses verkehrt.

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.
Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead r

MFG
Chali

mal einer sagen,ob hier nur die kurzfristigen zocker und Trader eingestiegen sind,oder ob das hier ein nachhaltiger fetter Rebound wird ?????? Ich hatte die Aktie im Verdacht insolvenzgefährdet zu sein und bin deshalb vorsichtshalber ausgestiegen,wer kenn sich mit den Zahlen besser aus als ich ?

Hi Chali, ich kann Dir da leider auch nichts zu sagen.

Bei iHub sind die Meinungen(wie immer) unterschiedlich. Vielleicht hilft Dir ein Blick hinein.

Gruß

investorshub.advfn.com/Cardium-Therapeutics-Inc-CXM-16154/  

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.

Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead resistance levels at $1.35.

www.thestreet.com/story/12051324/4/...10-making-big-moves.html

IHUB ist doch der letzte Schwachzockerladen,die Meinungen dort sind doch nicht brauchbar: Diese Deppen haben STOA gemeinschaftlich in den Himmel gelobt mit 10.000% plus,seitdem hat sich die Aktie gezehntelt !!! Ja ? Alles klar ? Jetzt weisst du wie brauchbar IHUB ist !

P.S. Den Street artikel kenn ich schion,siehe #11

... diskutiert. Manche Forenteilnehmer vermuten Großes, andere eher das Schlimmste. Jedenfalls tobt es dort ziemlich. Gut, das ist in Yahoo Finance Foren oft so, aber ich wüsste gern mal, wie ihr die Lage seht.

Ein Blick auf Cardium lohnt sich. Der 5-Jahres-Chart zeigt zwar nach unten, ein Rebound könnte aber bevorstehen. Der Kurs ist schon ganz schön in den Keller gerutscht.
Eine positive Meldung und es kann schnell mal 50% nach oben gehen...

Erstmalig sind die Umsätze bei CXM ins laufen gekommen bei knapp 2 mio,das kann aber noch deutlich mehr werden,denn Excellagen ist jetzt verparnert ! Ich würde folgende Strategie fahren: Wenn du mindestens 1000 Stück im Depot hast und es kommt zum Hype,dann würde ich im Bereich 2,50 - 3 dollar verkaufen.Das volumen ist nach wie vor sehr hoch und du gehst auf Nummer sicher,denn die finanzielle situation bei CXM scheint angespannt,es muss frisches Geld her. Von der Pipeline her ist CXM allerdings vom Feinsten ......

MFG
Chali

Was hier auffällt, ist die starke Abhängigkeit von den Cardium To Go Brands - 92% in Q1
und dass insgesamt noch rote Zahlen geschrieben werden.

Die pipeline, die Du ansprichst, wie sieht die eigentlich aus, Chalif?

For the three months ended March 31, 2013, the Company reported a lower net loss of $2.2 million, or $(0.02) per share, when compared to a net loss of $2.6 million, or $(0.02) per share for the three months ended March 31, 2012.  The decrease in net loss was due to cost reductions and increased sales revenue.  
Product sales for the three months ended March 31, 2013 totaled $599,000, compared to $20,000 for the same period in 2012. The increase in sales during the first quarter 2013 reflects sales from Cardium's To Go Brands health science-based operating unit (representing approximately 92% of total product sales) and sales of Cardium's Excellagen advanced wound care product (8% of total product sales).  

For the three months ended June 30, 2013, the Company reported a net loss of $2.1 million, or $(0.37) per share, when compared to a net loss of $1.9 million, or $(0.31) per share for the three months ended June 30, 2012.
Product sales for the three months ended June 30, 2013 totaled $585,000, compared to $13,000 for the same period in 2012. Product sales for the six months ended June 30, 2013 were $1.2 million, compared to $34,000 for the six months ended June 30, 2012.  The increase in product sales was comprised of sales from the Company's To Go Brands health sciences business, which Cardium acquired in late September 2012.  

die Zahlenjobs bei CRME und CXM. OK,du bist neu in biotech,aber die Zahlen interessieren hier bei CRME im Moment wirklich keinen,das ist bei biotech oft so ! Vor 3 Jahren,als Merck noch beteiligt war,stand CRME bei 60 Dollar und geändert hat sich eigentlich nichts,ausser das Merck nicht mehr dabei ist,ich werde unter 40 Dollar meine CRME nicht hergeben !!

From a technical perspective, CXM bounced sharply higher here right off some near-term support at 72 cents with strong upside volume. This stock recently formed a double bottom chart pattern at 69 cents to 70 cents. Following that bottom, shares of CXM have started to rebound higher and move within range of triggering a major breakout trade. That trade will hit if CXM manages to take out some near-term overhead resistance levels at 86 cents to 92 cents, and then 96 cents with high volume.

Traders should now look for long-biased trades in CXM as long as it's trending above support at 70 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 68,300 shares. If that breakout hits soon, then CXM will set up to re-test or possibly take out its next major overhead resistance levels at $1.35.
Quelle: www.thestreet.com/story/12051324/4/...10-making-big-moves.html

So gesehen, sieht es ganz gut aus. Denn wir notieren ja klar über 1,00 USD

CXM hat im moment kein Geld,um die Pipline voranzutreiben und weiterzuentwickeln. Am interessantesten finde ich Generx in Phase-3. Das DNA Produkt zielt darauf ab,die Bypass Operationen abzulösen,ein Herzmedikament,das der Knaller schlechthin werden könnte. KÖNNTE !

... doch auch nicht. Denn wenn uns nur die "medizin-wissenschaftliche" pipeline bleibt, dann sind wir Non-Docs doch komplett außen vor. Mir gefällt bei CXM immerhin, dass sie ihre Pläne aus dem Abschlussbericht 2012 sehr schön verwirklicht haben. Eigentlich sollte sich allmählich auch wirtschaftlich einges tun. Und wenn das absehbar wird, dann kommt auch der Kurs aus'm Kreuz.

"Value in a biotechnology company's pipeline is not seen in current price per share but rather in projected value of the biotechnology company's intellectual property."

Das ist es, was Du meinst. Nicht wahr, Chalif

diese aussgae kann ich nicht nachvollziehen,denn dann müsste CXM mindestens 10 oder 100 mal so hoch stehen ......